Loading
Loading
Research Overview
Khavinson tetrapeptide targeted at prostate gland tissue; proposed to normalise prostate cell metabolism and modulate inflammatory gene expression, with studies suggesting efficacy in benign prostatic hyperplasia models.
Testagen is a short synthetic peptide belonging to the class of tissue-specific peptide bioregulators originally described in Russian and Eastern European gerontology research. It is composed of a defined amino acid sequence designed to mirror naturally occurring regulatory peptides isolated from mammalian endocrine tissues, particularly the testes. Testagen does not function as a hormone and is not known to directly activate classical endocrine receptors. Instead, it has been investigated as a gene-regulatory signaling peptide capable of influencing transcriptional activity within endocrine and reproductive tissues under experimental conditions.
The development of Testagen emerged from research limitations associated with traditional hormone replacement approaches. Exogenous hormones often act systemically, engage multiple receptor populations, and disrupt endogenous feedback mechanisms. In contrast, peptide bioregulators were proposed as low-molecular-weight signals capable of modulating tissue-specific gene expression without directly substituting for endogenous hormones. Testagen was synthesized to study whether short peptides could selectively interact with nuclear DNA motifs or chromatin-associated proteins in testicular cells, thereby influencing transcriptional programs relevant to endocrine function.Preclinical investigations of Testagen have primarily involved in vitro cell culture systems and animal models. In these experimental contexts, Testagen exposure has been associated with changes in gene expression related to steroidogenesis, spermatogenesis, and cellular differentiation within testicular tissue. Studies have reported modulation of genes involved in testosterone synthesis pathways, Sertoli cell function, and germ cell maturation relative to untreated controls. These observations were derived from molecular assays, histological analyses, and transcriptional profiling rather than functional reproductive outcomes.
All available data on Testagen are preclinical. The peptide has not been evaluated in human clinical trials and is not approved for human use. Its relevance remains limited to experimental research exploring peptide-mediated gene regulation within endocrine and reproductive systems.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, testagen has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Testagen research is most relevant to protocols examining:
Prostate health and benign prostatic hyperplasia research
Androgenic tissue-specific bioregulator studies
Prostate cell metabolism and inflammatory gene expression investigations
Researchers studying Khavinson bioregulators for male reproductive health
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Khavinson tetrapeptide targeted at prostate gland tissue; proposed to normalise prostate cell metabolism and modulate inflammatory gene expression, with studies suggesting efficacy in benign prostatic hyperplasia models.
| Parameter | Value |
|---|---|
| Dose range | 10–20 mg/day (cycled) |
| Schedule | Daily (cycled) |
| Route | Subcutaneous |
| Half-life | ~Hours |
avoid
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.